BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Empire Genomics Buys Product to Aid Cancer Research


12/6/2012 8:51:28 AM

Empire Genomics LLC has acquired an exclusive license from Emory University to genomic biomarkers to be used to determine treatments for cancer patients. The Buffalo-based firm, which specializes in personalized medicine, will use the patent-pending biomarkers to develop molecular diagnostic tests that could help satisfy an unmet need for therapeutic treatments for patients with multiple myeloma, a malignant blood cell cancer. Terms of the purchase were not disclosed. Empire Genomics announced last month it is commercializing a genetic test for multiple myeloma designed to help physicians select the right drug therapies based on the individual patients’ genetic markers. This new diagnostic test, company officials said, will be the first DNA biomarker test to direct treatment of multiple myeloma. The biomarkers were developed by Dr. Leon Bernal-Mizrachi, an assistant professor of hematology and medical oncology at the Emory University School of Medicine. Anthony Johnson, Empire Genomics CEO, said in a media release the company will also explore the use of this biomarker in lymphoma patients as well.

Read at News Release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->